Beijing, June 5, 2026– Today, the first batch of imported Cevira® (Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System), the world’s first non-surgical, non-invasive therapy approved for cervical intraepithelial neoplasia grade 2 (CIN2)1, has been officially dispatched to destinations across China following successful inspection and customs clearance at the Beijing port. The entire process was supported by SPH Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (SPH Kyuan Trade), which provided comprehensive professional pharmaceutical distribution services. The first batch is now being shipped to distributors and medical terminals nationwide, meaning that CIN2 patients in China – especially those of childbearing age – will soon have access to a new treatment option that “requires no surgery and preserves fertility”. On the same day, the first global prescription of Cevira® was issued in Beijing.
Notably, Cevira® has taken only three months from NMPA approval in March to its first shipment in June. As the world’s first non-surgical, non-invasive therapy, the product is subject to both drug inspection and medical device inspection – a more complex process than a single-category product – which fully demonstrates the collaborative efficiency and supply chain capabilities of all parties involved.
March 3, 2026 – Cevira® has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA) for its commercial launch
May 4, 2026 – First batch of Cevira® arrived at Beijing port
June 3, 2026 – Drug inspection report efficiently issued, statutory import inspection completed
June 5, 2026 – First shipment of Cevira® dispatched, with the first global prescription issued in Beijing on the same day
Cervical precancerous lesions are most prevalent among women of childbearing age (25–40 years). For a long time, clinical practice has faced a dilemma between “to excise or not to excise”: surgery, while effective, removes part of the cervical tissue and may increase the risk of future miscarriage or preterm birth; on the other hand, active surveillance alone places patients under psychological stress due to the risk of disease progression.
Cevira® is an innovative, non-invasive, portable photodynamic drug-device combination product. It can be administered by a gynecologist in an outpatient setting without anesthesia, with a single treatment session taking less than 10 minutes. Patients can “treat and go” – no hospitalization, no anesthesia, and no interference with normal work or daily life after application. Approved by the NMPA in March this year, Cevira® is the world’s first and only non-invasive therapy approved for the CIN2 indication, filling a critical clinical gap in this therapeutic area.
At today’s dispatch ceremony, logistics trucks loaded with Cevira® departed from the Beijing Tianzhu Comprehensive Bonded Zone. Asieris and SPH Kyuan Trade stated that the first batch will cover hundreds of hospitals nationwide, with subsequent batches to be shipped as planned to ensure a stable clinical supply.
With the official dispatch of the first batch and the successful issuance of the first prescription, CIN2 patients in China will soon have access to this non-invasive therapy at select hospitals in major cities. Many hospitals have indicated that they will take this opportunity to further establish “Cervical Care Demonstration Clinics” and promote the treatment philosophy of “non-invasive first, fertility preservation,” reshaping the current treatment landscape and contributing to the national effort to build a fertility-friendly society.
- Insight Database ↩︎